Studies showed increase of IL-6, monocyte chemotactic protein 1 (MCP-1), and tumor necrosis factor alpha (TNF-α) related to worse clinical outcomes in PAH patients. This evidence concerns the gene IL6 and pulmonary arterial hypertension.